Alnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024. In the quarter to June 2026, revenue grew 66.9%, EPS grew 341.2%, free cash flow grew 152.8% and total debt fell 1.51%, each against the same quarter a year earlier. Member of the Nasdaq 100; revenue growth for five consecutive years.
Follow ALNY
Alnylam Pharmaceuticals, Inc. (ALNY) EV/Sales
As of 16 October 2026, Alnylam Pharmaceuticals, Inc. (ALNY) trades at a EV/Sales of 6.0×. Over the past ten years it has ranged from 5.2× (July 2026) to 201× (August 2016); the current reading is higher than 1% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 13.5× | 7.11% |
| FY2024 | 12.6× | 0.61% |
| FY2023 | 12.5× | (52.25%) |
| FY2022 | 26.3× | 21.01% |
| FY2021 | 21.7× | (19.33%) |
| FY2020 | 26.9× | (47.78%) |
| FY2019 | 51.5× | (38.53%) |
| FY2018 | 83.8× | (26.67%) |
| FY2017 | 114× | 90.46% |
| FY2016 | 60.0× | (63.86%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.9× | (19.37%) |
| Mar 2026 | 9.8× | (27.56%) |
| Dec 2025 | 13.5× | (25.53%) |
| Sep 2025 | 18.1× | 9.60% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 1.8× |
| INCY Incyte Corporation compare | 3.1× |
| ALNY Alnylam Pharmaceuticals, Inc. | 6.0× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.1× |
| GMAB Genmab A/S Sponsored ADR compare | 6.4× |
| RPRX Royalty Pharma PLC compare | 14.0× |
| INSM Insmed, Inc. compare | 18.1× |
| RVMD Revolution Medicines, Inc. compare | 1,287× |
| ROIV Roivant Sciences Ltd. compare | 2,742× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)